Currently, referencing the European Society of Cardiology, pharmacotherapy for the management of HF includes the use of beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin-receptor blocker or angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists and sodium glucose co-transporter 2 inhibitors [70]. The gene discussed is NR3C2; the disease is hydrops fetalis.